Ginkgo Bioworks CFO Steven Coen sells $2,302 in stock By Investing.com

Steven P. Coen, Chief Financial Officer of Ginkgo Bioworks Holdings, Inc. (), reported the sale of shares totaling $2,302 on August 24, 2026. The transaction involved 330 shares of Class A Common Stock, sold at a price of $6.977 per share. The stock has since risen to $7.54, though it remains well below its 52-week high of $17.58. According to InvestingPro analysis, the company appears undervalued at current levels, with shares trading significantly below Fair Value. InvestingPro Tips highlight that the stock is quickly burning through cash, one of 7 additional insights available to subscribers.

These shares were sold to cover tax withholding obligations associated with the vesting of restricted stock and/or restricted stock units, and do not represent discretionary trades by Mr. Coen. The company’s equity incentive plans allow for satisfaction of tax withholding obligations through such “sell to cover” transactions.

Prior to this sale, on August 21, 2026, Mr. Coen acquired a total of 743 shares of Class A Common Stock through the vesting of restricted stock units (RSUs). This included 587 shares from units that began vesting on May 1, 2024, with 25% vesting initially, followed by 36 equal monthly installments. An additional 156 shares came from units that also began vesting on May 1, 2024, with 2/48ths vesting initially, followed by 46 equal monthly installments. Each restricted stock unit represents a contingent right to receive one share of the company’s Class A Common Stock.

Following these reported transactions, Mr. Coen directly holds 51,851 shares of Ginkgo Bioworks Holdings, Inc. Class A Common Stock.

In other recent news, Ginkgo Bioworks Holdings reported its financial results for the second quarter of 2026, revealing a smaller-than-expected loss but a significant revenue shortfall. The company posted an adjusted loss of $0.92 per share, which was better than the anticipated $1.05 loss, but its revenue of $20 million fell short of the $29.9 million forecast. This marked a 48% decline in revenue from the previous year, highlighting ongoing challenges as the company shifts its focus towards autonomous laboratory technology. Ginkgo Bioworks ended the quarter with $389 million in total liquidity and maintained its full-year cash burn guidance of $125 million to $150 million.

In related developments, TD Cowen downgraded Ginkgo Bioworks’ stock rating from Buy to Hold, citing uncertainty surrounding the company’s growth. The firm also adjusted its price target for the stock from $12.00 to $9.00. TD Cowen noted that while Ginkgo’s focus on Datapoints and Autonomous Labs has potential, it requires continued investment and time to realize benefits. Despite these challenges, Ginkgo Bioworks remains committed to expanding its autonomous labs, including the Nebula system in Boston. These recent developments underscore the company’s ongoing transformation efforts and the market’s cautious outlook.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.